HUTCHMED (China) HMDCF
NASDAQ HMDCF
$2.16 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

HUTCHMED (China) (HMDCF) Total Liabilities (2014 - 2026)

HUTCHMED (China)'s (HMDCF) quarterly Total Liabilities came in at $461.5 million in Q2 2026, down 13.59% year-over-year from $534.0 million in Q2 2025, and down 8.05% quarter-over-quarter from $501.8 million in Q4 2025.

Analysis

HUTCHMED (China) (HMDCF) Total Liabilities (2014 - 2026) Analysis & Trends

HUTCHMED (China) (HMDCF) has reported Total Liabilities for 13 consecutive years, with $461.5 million the latest figure, recorded in Q2 2026.

  • On a quarterly basis, Total Liabilities fell 13.59% year-over-year to $461.5 million in Q2 2026; TTM through Jun 2026 was $461.5 million, a 13.59% decrease from a year earlier, with the FY2025 full-year figure at $501.8 million, changed N/A from the prior year.
  • Total Liabilities was $461.5 million for Q2 2026 at HUTCHMED (China), down from $501.8 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $534.0 million in Q2 2025 and troughed at $342.5 million in Q2 2022.
  • A 5-year average of $462.7 million and a median of $497.5 million in 2023 frame the typical range for Total Liabilities.
  • Across the five-year window, Total Liabilities surged 45.26% in 2023 and slipped 13.59% in 2026, its largest moves.
  • Over 5 years, Total Liabilities stood at $392.6 million in 2022, then advanced by 26.72% to $497.5 million in 2023, then increased by 2.29% to $508.8 million in 2024, then fell by 1.38% to $501.8 million in 2025, then declined by 8.05% to $461.5 million in 2026.
  • The last three Total Liabilities figures came in at $461.5 million (Q2 2026), $501.8 million (Q4 2025), and $534.0 million (Q2 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Liabilities (Qtr)
1 Amgen 211.51 Bn 197.52 Bn 7.24 Bn 83.95 Bn
2 Gilead Sciences 181.48 Bn 178.30 Bn 6.22 Bn 37.53 Bn
3 Vertex Pharmaceuticals 132.45 Bn 124.60 Bn 2.84 Bn 7.18 Bn
4 Regeneron Pharmaceuticals 82.87 Bn 74.88 Bn 3.93 Bn 10.02 Bn
5 Argenx Se 61.59 Bn 56.41 Bn 1.37 Bn 1.62 Bn
6 Moderna 54.72 Bn 49.59 Bn 52.00 Mn 4.20 Bn
7 Alnylam Pharmaceuticals 34.13 Bn 30.82 Bn 992.69 Mn 4.20 Bn
8 Biogen 31.29 Bn 30.01 Bn 1.96 Bn 13.24 Bn
9 Roivant Sciences 30.31 Bn 30.31 Bn 1.16 Mn 384.62 Mn
10 HUTCHMED (China) 376.85 Mn 391.04 Mn - 461.46 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 461.46 Mn
Dec 31, 2025 501.84 Mn
Jun 30, 2025 534.02 Mn
Jun 30, 2024 508.85 Mn
Jun 30, 2023 497.48 Mn
Dec 31, 2022 392.58 Mn
Jun 30, 2022 342.48 Mn
Dec 31, 2021 333.15 Mn
Sep 28, 2021 -46.49 Mn
Jun 30, 2021 259.19 Mn
Mar 31, 2021 228.72 Mn
Dec 31, 2020 205.17 Mn
Jun 30, 2020 158.51 Mn
Dec 31, 2019 152.22 Mn
Sep 30, 2019 116.31 Mn
Jun 30, 2019 122.18 Mn
Mar 31, 2019 138.94 Mn
Dec 31, 2018 119.86 Mn
Sep 30, 2018 -424.70 Mn
Jun 30, 2018 120.10 Mn